You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
《異動股》來凱醫藥(02105.HK)續挫35%屢創上市新低
阿思達克 01-29 13:55
來凱醫藥-B(02105.HK)公布治療卵巢癌藥臨床試驗可降低死亡的風險,但試驗沒有達到統計學意義。該股連跌第九天兼屢創去年6月尾上市以來新低,承上周五挫21%頹勢,今天進一步挫至5.03元,現報5.07元,急跌35%,成交續增至591萬股,涉資3,296萬元。 來凱醫藥-B公布,afuresertib聯合紫杉醇在美國和中國治療鉑耐藥卵巢癌患者的國際多中心註冊二期臨床試驗頂線數據,試驗結果表明,afuresertib聯合紫杉醇周療可以降低疾病進展或死亡的風險,但試驗沒有達到統計學意義。
Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of this article is for reference only. It does not constitute an offer, solicitation, recommendation, opinion or guarantee of any securities, financial products or instruments.The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance.
uSMART
Wealth Growth Made Easy
Open Account